Cim Investment Management Inc. Has $948,000 Stake in Zoetis Inc. $ZTS

Key Points

• Cim Investment Management Inc. has significantly increased its stake in Zoetis Inc. by 99.9%, bringing its holdings to 5,786 shares valued at $948,000.
• Zoetis reported a quarterly revenue of $2.46 billion, exceeding analysts' expectations, along with an EPS of $1.76, surpassing consensus estimates by $0.14.
• Analysts have mixed views on Zoetis, with price targets ranging from $155 to $215, indicating a consensus "Moderate Buy" rating for the stock.

Cim Investment Management Inc. increased its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 99.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,786 shares of the company's stock after purchasing an additional 2,892 shares during the period. Cim Investment Management Inc.'s holdings in Zoetis were worth $948,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Nova Wealth Management Inc. acquired a new stake in Zoetis during the 1st quarter worth approximately $25,000. 1248 Management LLC acquired a new position in Zoetis in the 1st quarter valued at $27,000. Saudi Central Bank acquired a new position in Zoetis in the 1st quarter valued at $29,000. Cornerstone Planning Group LLC raised its holdings in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after acquiring an additional 88 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. raised its holdings in Zoetis by 87.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after acquiring an additional 120 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Price Performance

Zoetis stock opened at $150.66 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The stock has a market capitalization of $66.77 billion, a P/E ratio of 25.93, a price-to-earnings-growth ratio of 2.40 and a beta of 0.89. The stock has a fifty day moving average of $152.53 and a 200-day moving average of $157.45.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. During the same quarter in the previous year, the firm earned $1.56 EPS. Zoetis's revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on ZTS. Argus reaffirmed a "buy" rating and issued a $190.00 price objective on shares of Zoetis in a report on Tuesday. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and dropped their price objective for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, Piper Sandler lifted their price objective on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, Zoetis has a consensus rating of "Moderate Buy" and a consensus price target of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.